MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2011.34.7542

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011

Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.

Björkholm Magnus, Derolf Asa R, Hultcrantz Malin, Kristinsson Sigurdur Y, Ekstrand Charlotta, Goldin Lynn R, Andreasson Björn, Birgegård Gunnar, Linder Olle, Malm Claes, Markevärn Berit, Nilsson Lars, Samuelsson Jan, Granath Fredrik, Landgren Ola

СтатьяResearch Support, N.I.H., IntramuralПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Patients with myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have a propensity to develop acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs). Using population-based data from Sweden, we assessed the role of MPN treatment and subsequent AML/MDS risk with special focus on the leukemogenic potential of hydroxyurea (HU).

METHODS

On the basis of a nationwide MPN cohort (N = 11,039), we conducted a nested case-control study, including 162 patients (153 and nine with subsequent AML and MDS diagnosis, respectively) and 242 matched controls. We obtained clinical and MPN treatment data for all patients. Using logistic regression, we calculated odds ratios (ORs) as measures of AML/MDS risk.

RESULTS

Forty-one (25%) of 162 patients with MPNs with AML/MDS development were never exposed to alkylating agents, radioactive phosphorous (P(32)), or HU. Compared with patients with who were not exposed to HU, the ORs for 1 to 499 g, 500 to 999 g, more than 1,000 g of HU were 1.5 (95% CI, 0.6 to 2.4), 1.4 (95% CI, 0.6 to 3.4), and 1.3 (95% CI, 0.5 to 3.3), respectively, for AML/MDS development (not significant). Patients with MPNs who received P(32) greater than 1,000 MBq and alkylators greater than 1 g had a 4.6-fold (95% CI, 2.1 to 9.8; P = .002) and 3.4-fold (95% CI, 1.1 to 10.6; P = .015) increased risk of AML/MDS, respectively. Patients receiving two or more cytoreductive treatments had a 2.9-fold (95% CI, 1.4 to 5.9) increased risk of transformation.

CONCLUSION

The risk of AML/MDS development after MPN diagnosis was significantly associated with high exposures of P(32) and alkylators but not with HU treatment. Twenty-five percent of patients with MPNs who developed AML/MDS were not exposed to cytotoxic therapy, supporting a major role for nontreatment-related factors.

Для цитирования: Björkholm Magnus, Derolf Asa R, Hultcrantz Malin, Kristinsson Sigurdur Y, Ekstrand Charlotta, Goldin Lynn R, Andreasson Björn, Birgegård Gunnar, Linder Olle, Malm Claes, Markevärn Berit, Nilsson Lars, Samuelsson Jan, Granath Fredrik, Landgren Ola. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. DOI: 10.1200/jco.2011.34.7542.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.